NCT06586112Phase 3Completed

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2025-09-19Actual

Enrollment · participants912Actual

Source updated2026-08-10Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-04-13 · 3 fields changed

Participant count type changed

− Before

~~Estimated~~

+ After

Actual

Enrollment · participant count changed

− Before

~~840 participants (planned)~~

+ After

912 participants (actual)

Recruitment status changed

− Before

~~Active not recruiting~~

+ After

Completed

Check registry source

Posted 2025-11-10 · 2 fields changed

Completion date type changed

− Before

~~Estimated~~

+ After

Actual

Primary completion date changed

− Before

~~Sep 2025~~

+ After

19 Sep 2025

Check registry source

Study details

Conditions studied

Plaque Psoriasis

Treatments or interventions studied

EnvudeucitinibDrug
ApremilastDrug
PlaceboDrug

Primary outcomes · main study measures

measure: To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo; description: Proportion of participants achieving ≥75% reduction in PASI score. Proportion of participants achieving a score of 0 or 1 on sPGA.; timeFrame: 16 weeks

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history